Raptiva falloff weighs on Merck KGaA

Hit by a decline in demand for the psoriasis drug Raptiva--recently linked to the deaths of two patients who developed the rare brain infection PML (progressive multifocal leukoencephalopathy)--Merck KGaA posted a fourth-quarter loss of 279.5 million euros ($374 million). Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.